Protection through 2039, ensuring long-term commercial exclusivity.

NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the HT-KIT platform. The patent was officially granted by the Japan Patent Office on May 7, 2025, and exclusive protection is granted until August 27, 2039.

The granted patent, titled "Targeting KIT with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells," protects Hoth's novel approach of using splice-switching oligonucleotides (SSOs) to selectively disrupt KIT gene expression in mast cells—cells implicated in conditions ranging from chronic hives to rare cancers.